Presenting new therapeutic solutions to a global audience

Our platform has too much potential to keep it secret. Which is why we publish, inform, and present. After all, you want to know where your future therapies are starting.

Press contact

eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 99 0

Press contact

eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 99 0

Press releases

Eleva secures up to EUR 60 million to advance a drug candidate, appoints new board member

January 6, 2021

Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.

READ MORE

Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H

September 14, 2021

Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce sufficient quantities of factor H to cover all three clinical phases.

READ MORE

Navigo Proteins and Eleva Announce Successful Development of an Affinity Chromatography Resin Customized for the Efficient Purification of Human Complement-Factor H

March 16, 2021

Custom Affinity Chromatography Resin Promises High Yield Purification in Clinical and Commercial GMP Downstream Processing.

READ MORE

Meet us here

No event found!
Load More

In the press

Press kit

For non-commercial purposes only. Please only use the material in combination with Eleva GmbH copyright label.

Boilerplate

Based in Freiburg, Germany, Eleva develops novel biological therapies with its pharmaceutical partners. The privately-held company leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. Eleva has successfully developed drug candidates into clinical phases.

eleva Newsletter